---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001389"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:47:40.688098+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oncocyte amends lease; terminates extension right, sets expiry Oct 2027, schedules $1.7M LC reduction

## Summary
- Amendment entered Jan 2, 2025 with Induce Biologics and landlord Cushing Ventures.
- Original lease expires Oct 31, 2027; all extension rights cancelled.
- Letter of credit reduced by $60,714.29/month starting July 1, 2025 from $1.7M.
- Reduction contingent on no continuing default; no assurance of reduction.
- Reductions correspond to restricted cash on balance sheet.

## SEC filing metadata
- accession: 0001493152-25-001389
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315225001389/0001493152-25-001389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315225001389/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001389
- JSON: https://secwatch.observer/filing/0001493152-25-001389.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.